vimarsana.com
Home
Live Updates
Roche's BTK inhibitor fenebrutinib significantly reduced bra
Roche's BTK inhibitor fenebrutinib significantly reduced bra
Roche's BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis
Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis trialsPhase... | May 17, 2023
Related Keywords
United States ,
Switzerland ,
Japan ,
America ,
Loren Kalm ,
Levi Garraway ,
Kirti Pandey ,
Nathalie Altermatt ,
Genentech ,
Roche Group ,
Roche Group Media Relations ,
Head Of Global Product Development ,
Chief Medical Officer ,
Global Product ,
Dow Jones Sustainability Indices ,
Chugai Pharmaceutical ,
Roche Holding Ag Stock Exchange ,
News ,
Information ,
Press Release ,
Fenebrutinib ,
Us ,
N ,
Kpotent ,
End ,
Ighly ,
Elective ,
Mural ,
Tyrosine ,
Inase ,
The ,
Only ,
Irreversible ,
Stk ,
Inhibitor ,
Currently ,
Hase ,
Wii ,
Multiple ,
Clerosis Ro Ch0012032113 ,